Sunovion announced that Latuda (lurasidone HCl) is available for the treatment of adults with schizophrenia. Latuda, a once daily atypical antipsychotic, is a mixed dopamine D2 and serotonin 5HT2A receptor antagonist. It was first approved by the FDA on October 28, 2010.

Latuda is available in 40mg and 80mg dosage strength tablets.

For more information call (800) 739-0565 or visit www.latuda.com.